Standard BioTools announces multi-year agreement with Bristol Myers

Standard BioTools (LAB) announced that it has entered into a multi-year engagement with global biopharmaceutical company Bristol Myers Squibb (BMY) for use of the SomaScan Platform as a tool for clinical trials in multiple therapeutic areas through 2026. “Bristol Myers Squibb is focused on the discovery and development of medicines that have the potential for transformational patient outcomes, and to achieve that end, we understand how critical it is to prospectively identify the patient populations most likely to benefit from our therapies,” says Peter Schafer, Scientific VP, Translational Medicine, Bristol Myers Squibb. “Leveraging the SomaScan Platform in clinical trials enables important progress toward defining the path to clinical proof-of-concept for our pipeline, helping to increase the probabilities of success in providing important new medicines for patients in need.”